160 results about "Movement disorders" patented technology

The invention discloses a construction method of a dyskinesia phenotype classification model of a Parkinson's disease patient and a diagnosis system, and belongs to the field of medical auxiliary diagnosis devices. The system comprises an image acquisition module and a phenotype classification module, wherein the classification module is composed of a space-time diagram convolution feature extraction module, a hierarchical node fusion module, a functional brain network construction and feature extraction module, a local brain region feature screening module, a hierarchical brain feature pairing fusion module and an output module. According to the method, multi-modal brain image data are fused, space-time and complex relation characteristics of a brain region are deeply mined, a key lesion brain region is positioned, and dyskinesia phenotypes are accurately classified by training a neural network. The system can significantly improve the diagnosis accuracy of the Parkinson's disease dyskinesia phenotype, has good expansibility and adaptability, and provides a scientific basis for early diagnosis and personalized intervention. The invention further relates to an operation method of the system, an auxiliary diagnosis device and a computer readable storage medium.

A system for tuning the parameters of a therapeutic medical device comprises a movement measurement data acquisition system capable of wireless transmission; processing comprising kinematic feature extraction, a scoring algorithm trained using scores from expert clinicians, a therapeutic device parameter setting adjustment suggestion algorithm preferably trained using the parameter setting adjustment judgments of expert clinicians; and a display and / or means of updating the parameter settings of the treatment device. The invention facilitates the treatment of movement disorders including Parkinson's disease, essential tremor and the like by optimizing deep brain stimulation (DBS) parameter settings. The system provides recommendations for treatment which may be semi-automatically or automatically applied to update the parameter settings of a treatment device such as a DBS implant.

A neurostimulation system may include an implantable neurostimulator. An implantable neurostimulator may include a first sensor configured to sense internal data relating to a symptom of a neurological movement disorder of a patient. An implantable neurostimulator may include an internal stimulator configured to provide an internal stimulation output to an internal target area of a patient. An implantable neurostimulator may include a first wireless communication device configured to communicate internal data with a network. A neurostimulation system may include a wearable neurostimulator. A wearable neurostimulator may include a second sensor configured to sense external data of a patient. A wearable neurostimulator may include an external stimulator configured to provide an external stimulation output to an external target area of a patient. A wearable neurostimulator may include a second wireless communication device configured to communicate external data with a network and receive internal data from the network.

Systems and methods for providing recommended doses and instructions for pharmaceutical treatments, and more particularly systems and methods for measuring physiological and / or electrophysiological signals from a subject and providing recommended doses and instructions of pharmaceuticals based at least in part on the measured signals are described. Further, the recommended doses and instructions are based at least in part on a subject's disease(s), disorder(s), or injuries and / or symptom(s) of such, and / or side effects of medications or treatments the subject is receiving. The recommended doses and instructions are personally tailored to the subject to precisely and personally address the subject's needs, and may be based in part on correlation with database(s) comprising historical data of the subject and / or other subjects to treat the subject's movement disorders, injuries to the body or brain, cognitive diseases and disorders, sleep diseases and disorders, chronic pain, or other conditions.

The present invention relates to methods for remotely tuning treatment parameters in movement disorder therapy systems where the subject and clinician are located remotely from each other. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

A multimodal wearable band which uses mechanical vibrations to stimulate sensory neurons in the wrist or ankle in order to reduce the severity of tremors, rigidity, involuntary muscle contractions, and bradykinesia caused by neurological movement disorders and to free users from freezing induced by movement disorders. The device uses sensors to provide output used by a processing unit to determine the optimal stimulation pattern for each user and to determine when stimulation is necessary, and then uses one or more vibration motors to accordingly stimulate the user's neurological pathways to lessen the severity of a user's symptoms. The device can also be adapted to integrate with 3rd party devices.

A multimodal wearable band uses mechanical vibrations to stimulate sensory neurons in the wrist or ankle to reduce the severity of tremors, rigidity, involuntary muscle contractions, and bradykinesia caused by neurological movement disorders and to free users from freezing induced by movement disorders. The device uses sensors to provide output used by a processing unit to determine a stimulation pattern for the user and to determine when stimulation is necessary, and then uses one or more transducers to correspondingly stimulate the user's neurological pathways to lessen the severity of the user's symptoms. The device can also be adapted to integrate with third party devices.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

A peripheral nerve stimulator to stimulate a peripheral nerve to treat essential tremor and other movement disorders, as well as overactive bladder, cardiac dysfunction and neurotransmitter dysfunction is provided. The peripheral nerve stimulator can be a noninvasive surface stimulator to provide multi-modal optimized therapy. Stimulation can be vibrational, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, light, mechanical, chemical, thermal, ultrasonic, radiofrequency (RF), acoustic, infrared, ultraviolet, x-ray, and / or microwave. Stimulation can be delivered using an open loop system and / or a closed loop system with feedback. Stimulation can be to one site or multiple sites.

A multimodal wearable band uses mechanical vibrations to stimulate sensory neurons in the wrist or ankle to reduce the severity of tremors, rigidity, involuntary muscle contractions, and bradykinesia caused by neurological movement disorders and to free users from freezing induced by movement disorders. The device uses sensors to provide output used by a processing unit to determine a stimulation pattern for the user and to determine when stimulation is necessary, and then uses one or more transducers to correspondingly stimulate the user's neurological pathways to lessen the severity of the user's symptoms. The device can also be adapted to integrate with third party devices.

Disclosed are compounds, and corresponding methods of treatment, that activate myocyte-specific enhancer factor 2 (MEF2) transcriptional activity that are therefore useful in treating deficits in MEF2C activity found in autism spectrum disorder (ASD), intellectual disability (ID), attention deficit and hyperactivity disorder (ADHD), and in diseases characterized by cognitive decline such as Alzheimer's disease (AD), Lewy body dementia (LED), Frontotemporal dementia (FTD), and other forms of dementia, as well as movement disorders such as Parkinson's disease (PD) and parkinsonism from other causes.

The invention discloses a weight loss gait test evaluation and training device and method, and the device comprises a weight loss control module which is used for weighing the weight of a user in real time and automatically adjusting the air pressure of an air bag according to a set weight loss proportion; the gait information acquisition module is used for synchronously acquiring plantar pressure distribution, lower limb joint kinematics parameters and double-view video data; the multi-modal gait evaluation grading model module is used for processing plantar pressure distribution, lower limb joint kinematics parameters and double-view video data and outputting lower limb dyskinesia grades; and the training scheme generation model module is used for automatically generating a training scheme including a weight reduction proportion, a treadmill speed, single exercise time and training times per week according to the lower limb dyskinesia level and the personal information of the user.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

To provide a motion analysis device that can be used for evaluating a motor function or motion disorder.SOLUTION: A motion analysis device (20) includes elbow flexure ratio calculation means (222) for calculating an elbow flexure ratio of an upper limb in elevation exercise which is expressed by an expression (1) or an expression (2) from respective three-dimensional coordinate data of the shoulder, elbow, and hand of a person to be evaluated when the person to be evaluated is in upper limb elevation exercise. In the expression (2), SH represents a vector from the shoulder to the hand, SE represents a vector from the shoulder to the elbow, and EH represents a vector from the elbow to the hand.SELECTED DRAWING: Figure 1

In an embodiment, a method of reducing movement disorder symptom severity of a patient is presented. A method may include securing a wearable device to a body part of a patient through an attachment system. A method may include activating a mechanical transducer of a wearable device to provide a vibratory output to one or more nerves in a vicinity of a wrist of the patient. A vibratory output may have a vibrational strength of about 0.30 Grms to about 0.78 Grms.

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The utility model relates to the field of rehabilitation training devices, in particular to a visual simple tongue pressure measuring and rehabilitation training device which comprises a tongue pressure measuring tube, a baffle is detachably installed on one side of the tongue pressure measuring tube in a sealed mode, and an airtight piston plate is connected into the tongue pressure measuring tube in a sealed and sliding mode. An elastic piece is arranged between the airtight piston plate and the baffle, and a gas pressure value metering mark is arranged on the tongue pressure measuring tube and matched with the airtight piston plate to be used for displaying a pressure value; one side of the tongue pressure measuring tube is communicated with a first connecting tube, and the first connecting tube is communicated with a tongue pressure positive pressure air bag; the baffle is provided with an air outlet communicated with the interior of the tongue pressure measuring pipe, and the air outlet is communicated with a fourth connecting pipe. The device is low in price and convenient to operate, tongue pressure can be accurately and visually measured and trained, and more convenient and practical rehabilitation training is provided for patients with dysphagia and tongue movement disorder.

The invention relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injections carrying novel artificial chemical genetics receptor gene sequences, and a combinatorial chemical genetics scheme formed by the injections and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of sheep monitoring, in particular to a method for monitoring the health state of sheep through gait recognition, which comprises the following steps: acquiring a sheep walking video stream through a camera, reconstructing and generating a three-dimensional skeleton motion sequence based on a skeleton motion track, and marking space-time coordinates of hip joint, knee joint and hoof key points; according to the three-dimensional skeleton motion sequence, the knee joint buckling angular velocity peak value, the same-side front and rear hoof grounding time difference and the trunk lateral swing amplitude in a single-step period are calculated, and a gait space-time coordination parameter set is constructed; and inputting the gait time-space coordination parameter set into a disease decoupling model based on anti-factual reasoning, and outputting an early arthritis risk index and a neurological dyskinesia probability. According to the invention, the arthritis risk index and the neurological dyskinesia probability are calculated, early recognition and risk grading early warning of dyskinesia are realized, and the intelligent level and the response capability of a health monitoring system are remarkably improved.

The invention provides a Parkinson's disease detection method and system based on plantar pressure diagram modeling. The method comprises the following steps: S1, dividing an original plantar pressure signal into a time slice sequence with a fixed length; step S2, converting each time slice in the time slice sequence into a plantar pressure diagram, step S3, inputting the plantar pressure diagram into a multi-level residual image convolutional network to perform multi-order spatial feature extraction, and outputting multi-scale spatial features; s4, splicing the output multi-scale spatial features into a time sequence according to a time sequence, inputting the time sequence into a Transform encoder, and outputting global time sequence features; and S5, based on the global time sequence features, outputting a Parkinson disease recognition result. According to the method, the detection efficiency can be effectively improved, subjective factor interference is reduced, the model generalization ability is enhanced, and reliable technical support is provided for objective detection of dyskinesia diseases such as Parkinson's disease.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses an exoskeleton robot rehabilitation parameter dynamic evaluation method and system based on gait quantitative analysis, and the method achieves the precise matching of a closest reference standard for a patient through an intelligent reference matching algorithm based on the dynamic reference matching technology of height and weight, and achieves the personalized adaptation of an evaluation reference. Misjudgment caused by an evaluation mode only depending on doctor experience is avoided, rehabilitation training parameters better fit actual physiological features of a patient, meanwhile, through a multi-dimensional gait scoring model, angle deviation analysis and bilateral coordination evaluation are fused, left and right joint activities are paired and defined, and a bilateral limb activity difference value is calculated, so that the rehabilitation training accuracy is improved. The asymmetric dyskinesia of a hemiplegic patient is accurately identified, a quantitative basis is provided for making a rehabilitation scheme, accurate judgment is performed according to own data characteristics of different users, and a rehabilitation treatment scheme is customized for the users by using quantitative data reference, so that the consistency and accuracy of the rehabilitation effect are ensured.

A method comprising to analyze the captured video data of the patient's body parts and to generate patient motion metrics, patient posture metrics, and patient gait metrics for each exercise routine completed by the patient based on the analyzed video data; store, in a database, the generated patient motion metrics, the patient posture metrics and the patient gait metrics for each of the completed exercise routines, wherein the generated patient motion metrics, the generated patient posture metrics and the generated patient gait metrics are used to track patient progress during physical therapy sessions, diagnose movement disorders, and provide personalized, data-driven treatment plans to enhance immediate outcomes and long-term recovery with respect to the musculoskeletal and neurological disorders; apply motion amplification algorithms to enhance the additional video data to provide clarity of tremor movements; apply edge detection to enhance tremor movement boundaries and detection; generate tremor amplitude measurements and tremor frequency measurements based on the motion amplification and edge detection algorithms; and store, in the database, the generated tremor amplitude measurements and tremor frequency measurements, wherein the generated tremor amplitude measurements and tremor frequency measurements are analyzed for diagnosis and monitoring of disorders such as Parkinson's disease and Essential Tremor.

A method for facilitating a Parkinson's Disease (“PD”) assessment of a patient includes capturing first video of a patient performing first test movements while holding the mobile device; capturing second video of the patient performing second test movements while maintaining the mobile device on their person; capturing third video of the patient performing third test movements including standing and walking; capturing one or more IMU readings using an IMU of the mobile device; processing the first video, the second video, and the third video according to (i) a hand landmark model to generate one or more hand biomarkers, (ii) a face landmark model to generate one or more face biomarkers, and (iii) a body landmark model to generate one or more body biomarkers; and determining an assessment score based on a standardized PD assessment by processing the biomarkers.

A method of treating a patient suffering from over-active bladder (OAB) or other urinary or bowel movement disorder includes placing at least one thermal device on an exterior portion of the patient's body proximate to the patient's saphenous nerve or the patient's tibial nerve. The thermal device includes a number of heating elements and a number of cooling elements arranged in a thermal array. The method also includes activating the heating elements and the cooling elements to stimulate the saphenous nerve and / or the tibial nerve to alleviate symptoms of the over-active bladder or the other urinary or bowel movement disorder.

The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Disclosed are a dual regulator for mGluR5 and HDAC6 and use thereof. More specifically, disclosed are a compound that simultaneously regulates mGluR5 and HDAC6, and use thereof as a therapeutic agent for movement disorders.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Disclosed examples relate to a system and method for creating and integrating self-supervised learning (SSL) digital movement biomarkers into electronic health records (EHRs) for enhanced diagnostic support and treatment monitoring, particularly for rare diseases and movement disorders. Example systems employ SSL techniques to analyze video data, tracking body key points and extracting kinematic data without the need for human-labeled annotations. Disclosed examples generate digital movement biomarker profiles that quantify symptoms and track disease progression, facilitating the objective measurement of drug impacts on symptoms. Example systems include components for video processing, compliance checking, pose estimation, context analysis, kinematic measurement, and classification. The digital movement biomarker profiles are stored securely and made accessible for clinical use, offering a novel approach to personalized medicine by enabling the identification of disorder-specific traits and symptom similarities across different disorders.

Treatments of neuromuscular conditions, activity-induced muscle damage, metabolic myopathies, and movement disorders with compositions comprising 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (Compound 1), as well as solid forms of Compound 1, and pharmaceutical compositions of Compound 1, and kits of Compound 1, are described herein.